PANCREATIC ADENOSQUAMOUS CARCINOMA
Clinical trials for PANCREATIC ADENOSQUAMOUS CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PANCREATIC ADENOSQUAMOUS CARCINOMA trials appear
Sign up with your email to follow new studies for PANCREATIC ADENOSQUAMOUS CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for pancreatic cancer: targeted drug combo enters phase 3 trial
Disease control Recruiting nowThis study tests a new drug called daraxonrasib, either alone or with standard chemotherapy, for people with metastatic pancreatic cancer that has spread. About 900 adults with a RAS gene mutation will be randomly assigned to one of three treatment groups. The goal is to see if t…
Matched conditions: PANCREATIC ADENOSQUAMOUS CARCINOMA
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New hope for pancreatic cancer: targeted pill may double remission time
Disease control Recruiting nowThis study tests whether a daily pill called olaparib can keep pancreatic cancer from returning after surgery and chemotherapy. It is for people whose tumors have specific gene mutations (BRCA1, BRCA2, or PALB2). About 152 participants will receive either olaparib or a placebo fo…
Matched conditions: PANCREATIC ADENOSQUAMOUS CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:46 UTC